APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal

Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.

Selected research

Market Analysis & Forecast

Global Gastrointestinal Market Analysis and Forecast 2026-2032

23 December 2025198 pages

Choose your research edition.

Industry ResearchGastrointestinal Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.

Global Gastrointestinal key players include AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, etc. Global top five manufacturers hold a share over 25%.

Europe is the largest market, with a share about 45%, followed by Asia, and North America, both have a share over 45 percent.

Read the full market overview

In terms of product, Prescription Gastrointestinal Drug is the largest segment, with a share over 80%. And in terms of application, the largest application is Chronic Gastritis, followed by Peptic Ulcer, etc.

Report Includes

This report presents an overview of global market for Gastrointestinal, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gastrointestinal, also provides the revenue of main regions and countries. Of the upcoming market potential for Gastrointestinal, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastrointestinal revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gastrointestinal market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gastrointestinal revenue, projected growth trends, production technology, application and end-user industry.

Gastrointestinal Segment by Company

AstraZenec

Sanofi

Bayer

Pfizer

GlaxoSmithKline

Teva

Zeria（Tillotts）

Perrigo

Boehringer Ingelheim

Purdue Pharma

C.B. Fleet

Abbott

Jiangzhong

Xian-Janssen

Gastrointestinal Segment by Type

Prescription Gastrointestinal Drug

OTC Gastrointestinal Drug

Gastrointestinal Segment by Application

Chronic Gastritis

Functional Dyspepsia

Peptic Ulcer

Acute Gastroenteritis

Others

Gastrointestinal Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gastrointestinal in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gastrointestinal company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastrointestinal revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gastrointestinal Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prescription Gastrointestinal Drug Major Player Table 3. OTC Gastrointestinal Drug Major Player Table 4. Global Gastrointestinal Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Chronic Gastritis Major Player Table 6. Functional Dyspepsia Major Player Table 7. Peptic Ulcer Major Player Table 8. Acute Gastroenteritis Major Player Table 9. Others Major Player Table 10. Gastrointestinal Industry Trends Table 11. Gastrointestinal Industry Drivers Table 12. Gastrointestinal Industry Opportunities and Challenges Table 13. Gastrointestinal Industry Restraints Table 14. Global Gastrointestinal Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Gastrointestinal Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Gastrointestinal Market Share by Region (2021-2026) Table 17. Global Gastrointestinal Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Gastrointestinal Market Share by Region (2027-2032) Table 19. Global Gastrointestinal Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Gastrointestinal Revenue Market Share by Players (2021-2026) Table 21. Global Gastrointestinal Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Gastrointestinal Key Players Headquarters & Area Served Table 23. Global Gastrointestinal Players, Product Type & Application Table 24. Global Gastrointestinal Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Gastrointestinal by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Gastrointestinal Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gastrointestinal Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Gastrointestinal Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Gastrointestinal Revenue Market Share by Type (2021-2026) Table 31. Global Gastrointestinal Revenue Market Share by Type (2027-2032) Table 32. Global Gastrointestinal Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Gastrointestinal Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Gastrointestinal Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Gastrointestinal Revenue Market Share by Application (2021-2026) Table 36. Global Gastrointestinal Revenue Market Share by Application (2027-2032) Table 37. AstraZenec Company Information Table 38. AstraZenec Business Overview Table 39. AstraZenec Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. AstraZenec Gastrointestinal Product Portfolio Table 41. AstraZenec Recent Development Table 42. Sanofi Company Information Table 43. Sanofi Business Overview Table 44. Sanofi Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sanofi Gastrointestinal Product Portfolio Table 46. Sanofi Recent Development Table 47. Bayer Company Information Table 48. Bayer Business Overview Table 49. Bayer Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Bayer Gastrointestinal Product Portfolio Table 51. Bayer Recent Development Table 52. Pfizer Company Information Table 53. Pfizer Business Overview Table 54. Pfizer Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Pfizer Gastrointestinal Product Portfolio Table 56. Pfizer Recent Development Table 57. GlaxoSmithKline Company Information Table 58. GlaxoSmithKline Business Overview Table 59. GlaxoSmithKline Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. GlaxoSmithKline Gastrointestinal Product Portfolio Table 61. GlaxoSmithKline Recent Development Table 62. Teva Company Information Table 63. Teva Business Overview Table 64. Teva Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Teva Gastrointestinal Product Portfolio Table 66. Teva Recent Development Table 67. Zeria（Tillotts） Company Information Table 68. Zeria（Tillotts） Business Overview Table 69. Zeria（Tillotts） Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Zeria（Tillotts） Gastrointestinal Product Portfolio Table 71. Zeria（Tillotts） Recent Development Table 72. Perrigo Company Information Table 73. Perrigo Business Overview Table 74. Perrigo Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Perrigo Gastrointestinal Product Portfolio Table 76. Perrigo Recent Development Table 77. Boehringer Ingelheim Company Information Table 78. Boehringer Ingelheim Business Overview Table 79. Boehringer Ingelheim Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Boehringer Ingelheim Gastrointestinal Product Portfolio Table 81. Boehringer Ingelheim Recent Development Table 82. Purdue Pharma Company Information Table 83. Purdue Pharma Business Overview Table 84. Purdue Pharma Gastrointestinal Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Purdue Pharma Gastrointestinal Product Portfolio Table 86. Purdue Pharma Recent Development Table 87. C.B. Fleet Company Information Table 88. C.B. Fleet Business Overview Table 89. C.B. Fleet Gastrointestinal Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. C.B. Fleet Gastrointestinal Product Portfolio Table 91. C.B. Fleet Recent Development Table 92. Abbott Company Information Table 93. Abbott Business Overview Table 94. Abbott Gastrointestinal Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Abbott Gastrointestinal Product Portfolio Table 96. Abbott Recent Development Table 97. Jiangzhong Company Information Table 98. Jiangzhong Business Overview Table 99. Jiangzhong Gastrointestinal Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Jiangzhong Gastrointestinal Product Portfolio Table 101. Jiangzhong Recent Development Table 102. Xian-Janssen Company Information Table 103. Xian-Janssen Business Overview Table 104. Xian-Janssen Gastrointestinal Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Xian-Janssen Gastrointestinal Product Portfolio Table 106. Xian-Janssen Recent Development Table 107. North America Gastrointestinal Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Gastrointestinal Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Gastrointestinal Revenue by Application (2021-2026) & (US$ Million) Table 110. North America Gastrointestinal Revenue by Application (2027-2032) & (US$ Million) Table 111. North America Gastrointestinal Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America Gastrointestinal Revenue by Country (2021-2026) & (US$ Million) Table 113. North America Gastrointestinal Revenue by Country (US$ Million) & (2027-2032) Table 114. Europe Gastrointestinal Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe Gastrointestinal Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe Gastrointestinal Revenue by Application (2021-2026) & (US$ Million) Table 117. Europe Gastrointestinal Revenue by Application (2027-2032) & (US$ Million) Table 118. Europe Gastrointestinal Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Europe Gastrointestinal Revenue by Country (2021-2026) & (US$ Million) Table 120. Europe Gastrointestinal Revenue by Country (US$ Million) & (2027-2032) Table 121. China Gastrointestinal Revenue by Type (2021-2026) & (US$ Million) Table 122. China Gastrointestinal Revenue by Type (2027-2032) & (US$ Million) Table 123. China Gastrointestinal Revenue by Application (2021-2026) & (US$ Million) Table 124. China Gastrointestinal Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Gastrointestinal Revenue by Type (2021-2026) & (US$ Million) Table 126. Asia Gastrointestinal Revenue by Type (2027-2032) & (US$ Million) Table 127. Asia Gastrointestinal Revenue by Application (2021-2026) & (US$ Million) Table 128. Asia Gastrointestinal Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Gastrointestinal Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 130. Asia Gastrointestinal Revenue by Region (US$ Million) & (2021-2026) Table 131. Asia Gastrointestinal Revenue by Region (US$ Million) & (2027-2032) Table 132. SAMEA Gastrointestinal Revenue by Type (2021-2026) & (US$ Million) Table 133. SAMEA Gastrointestinal Revenue by Type (2027-2032) & (US$ Million) Table 134. SAMEA Gastrointestinal Revenue by Application (2021-2026) & (US$ Million) Table 135. SAMEA Gastrointestinal Revenue by Application (2027-2032) & (US$ Million) Table 136. SAMEA Gastrointestinal Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. SAMEA Gastrointestinal Revenue by Country (2021-2026) & (US$ Million) Table 138. SAMEA Gastrointestinal Revenue by Country (US$ Million) & (2027-2032) Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Gastrointestinal Image Figure 2. Global Gastrointestinal Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prescription Gastrointestinal Drug Image Figure 5. OTC Gastrointestinal Drug Image Figure 6. Global Gastrointestinal Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Gastrointestinal Market Size Share 2021 VS 2025 VS 2032 Figure 8. Chronic Gastritis Image Figure 9. Functional Dyspepsia Image Figure 10. Peptic Ulcer Image Figure 11. Acute Gastroenteritis Image Figure 12. Others Image Figure 13. Global Gastrointestinal Market Size (US$ Million) & (2021-2032) Figure 14. Global Gastrointestinal Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Gastrointestinal Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Gastrointestinal Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Gastrointestinal Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Gastrointestinal Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Gastrointestinal Revenue Market Share by Type (2021-2032) Figure 21. Global Gastrointestinal Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Gastrointestinal Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Gastrointestinal Revenue Market Share by Application (2021-2032) Figure 24. North America Gastrointestinal Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Gastrointestinal Revenue Share by Type (2021-2032) Figure 26. North America Gastrointestinal Revenue Share by Application (2021-2032) Figure 27. North America Gastrointestinal Revenue Share by Country (2021-2032) Figure 28. United States Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Gastrointestinal Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Gastrointestinal Revenue Share by Type (2021-2032) Figure 33. Europe Gastrointestinal Revenue Share by Application (2021-2032) Figure 34. Europe Gastrointestinal Revenue Share by Country (2021-2032) Figure 35. Germany Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Gastrointestinal Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Gastrointestinal Revenue Share by Type (2021-2032) Figure 45. China Gastrointestinal Revenue Share by Application (2021-2032) Figure 46. Asia Gastrointestinal Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Gastrointestinal Revenue Share by Type (2021-2032) Figure 48. Asia Gastrointestinal Revenue Share by Application (2021-2032) Figure 49. Asia Gastrointestinal Revenue Share by Region (2021-2032) Figure 50. Japan Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Gastrointestinal Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Gastrointestinal Revenue Share by Type (2021-2032) Figure 58. SAMEA Gastrointestinal Revenue Share by Application (2021-2032) Figure 59. SAMEA Gastrointestinal Revenue Share by Country (2021-2032) Figure 60. Brazil Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Gastrointestinal Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Gastrointestinal Drug
  • OTC Gastrointestinal Drug
Applications
  • Chronic Gastritis
  • Functional Dyspepsia
  • Peptic Ulcer
  • Acute Gastroenteritis
  • Others
Companies covered
  • AstraZenec
  • Sanofi
  • Bayer
  • Pfizer
  • GlaxoSmithKline
  • Teva
  • Zeria（Tillotts）
  • Perrigo
  • Boehringer Ingelheim
  • Purdue Pharma
  • C.B. Fleet
  • Abbott
  • Jiangzhong
  • Xian-Janssen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gastrointestinal Market by Type
  3. 1.2.1 Global Gastrointestinal Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prescription Gastrointestinal Drug
  5. 1.2.3 OTC Gastrointestinal Drug
  6. 1.3 Gastrointestinal Market by Application
  7. 1.3.1 Global Gastrointestinal Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Chronic Gastritis
  9. 1.3.3 Functional Dyspepsia
  10. 1.3.4 Peptic Ulcer
  11. 1.3.5 Acute Gastroenteritis
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Gastrointestinal Market Dynamics
  1. 2.1 Gastrointestinal Industry Trends
  2. 2.2 Gastrointestinal Industry Drivers
  3. 2.3 Gastrointestinal Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gastrointestinal Market Perspective (2021-2032)
  2. 3.2 Global Gastrointestinal Growth Trends by Region
  3. 3.2.1 Global Gastrointestinal Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gastrointestinal Market Size by Region (2021-2026)
  5. 3.2.3 Global Gastrointestinal Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gastrointestinal Revenue by Players
  2. 4.1.1 Global Gastrointestinal Revenue by Players (2021-2026)
  3. 4.1.2 Global Gastrointestinal Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gastrointestinal Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gastrointestinal Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gastrointestinal Key Players Headquarters & Area Served
  7. 4.4 Global Gastrointestinal Players, Product Type & Application
  8. 4.5 Global Gastrointestinal Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gastrointestinal Market CR5 and HHI
  11. 4.6.3 2025 Gastrointestinal Tier 1, Tier 2, and Tier 3
5 Gastrointestinal Market Size by Type
  1. 5.1 Global Gastrointestinal Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gastrointestinal Revenue by Type (2021-2032)
  3. 5.3 Global Gastrointestinal Revenue Market Share by Type (2021-2032)
6 Gastrointestinal Market Size by Application
  1. 6.1 Global Gastrointestinal Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gastrointestinal Revenue by Application (2021-2032)
  3. 6.3 Global Gastrointestinal Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AstraZenec
  2. 7.1.1 AstraZenec Company Information
  3. 7.1.2 AstraZenec Business Overview
  4. 7.1.3 AstraZenec Gastrointestinal Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AstraZenec Gastrointestinal Product Portfolio
  6. 7.1.5 AstraZenec Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Gastrointestinal Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Gastrointestinal Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Bayer
  14. 7.3.1 Bayer Company Information
  15. 7.3.2 Bayer Business Overview
  16. 7.3.3 Bayer Gastrointestinal Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bayer Gastrointestinal Product Portfolio
  18. 7.3.5 Bayer Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Gastrointestinal Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Gastrointestinal Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Gastrointestinal Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Gastrointestinal Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Teva
  32. 7.6.1 Teva Company Information
  33. 7.6.2 Teva Business Overview
  34. 7.6.3 Teva Gastrointestinal Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Teva Gastrointestinal Product Portfolio
  36. 7.6.5 Teva Recent Developments
  37. 7.7 Zeria（Tillotts）
  38. 7.7.1 Zeria（Tillotts） Company Information
  39. 7.7.2 Zeria（Tillotts） Business Overview
  40. 7.7.3 Zeria（Tillotts） Gastrointestinal Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Zeria（Tillotts） Gastrointestinal Product Portfolio
  42. 7.7.5 Zeria（Tillotts） Recent Developments
  43. 7.8 Perrigo
  44. 7.8.1 Perrigo Company Information
  45. 7.8.2 Perrigo Business Overview
  46. 7.8.3 Perrigo Gastrointestinal Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Perrigo Gastrointestinal Product Portfolio
  48. 7.8.5 Perrigo Recent Developments
  49. 7.9 Boehringer Ingelheim
  50. 7.9.1 Boehringer Ingelheim Company Information
  51. 7.9.2 Boehringer Ingelheim Business Overview
  52. 7.9.3 Boehringer Ingelheim Gastrointestinal Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Boehringer Ingelheim Gastrointestinal Product Portfolio
  54. 7.9.5 Boehringer Ingelheim Recent Developments
  55. 7.10 Purdue Pharma
  56. 7.10.1 Purdue Pharma Company Information
  57. 7.10.2 Purdue Pharma Business Overview
  58. 7.10.3 Purdue Pharma Gastrointestinal Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Purdue Pharma Gastrointestinal Product Portfolio
  60. 7.10.5 Purdue Pharma Recent Developments
  61. 7.11 C.B. Fleet
  62. 7.11.1 C.B. Fleet Company Information
  63. 7.11.2 C.B. Fleet Business Overview
  64. 7.11.3 C.B. Fleet Gastrointestinal Revenue and Gross Margin (2021-2026)
  65. 7.11.4 C.B. Fleet Gastrointestinal Product Portfolio
  66. 7.11.5 C.B. Fleet Recent Developments
  67. 7.12 Abbott
  68. 7.12.1 Abbott Company Information
  69. 7.12.2 Abbott Business Overview
  70. 7.12.3 Abbott Gastrointestinal Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Abbott Gastrointestinal Product Portfolio
  72. 7.12.5 Abbott Recent Developments
  73. 7.13 Jiangzhong
  74. 7.13.1 Jiangzhong Company Information
  75. 7.13.2 Jiangzhong Business Overview
  76. 7.13.3 Jiangzhong Gastrointestinal Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Jiangzhong Gastrointestinal Product Portfolio
  78. 7.13.5 Jiangzhong Recent Developments
  79. 7.14 Xian-Janssen
  80. 7.14.1 Xian-Janssen Company Information
  81. 7.14.2 Xian-Janssen Business Overview
  82. 7.14.3 Xian-Janssen Gastrointestinal Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Xian-Janssen Gastrointestinal Product Portfolio
  84. 7.14.5 Xian-Janssen Recent Developments
8 North America
  1. 8.1 North America Gastrointestinal Revenue (2021-2032)
  2. 8.2 North America Gastrointestinal Revenue by Type (2021-2032)
  3. 8.2.1 North America Gastrointestinal Revenue by Type (2021-2026)
  4. 8.2.2 North America Gastrointestinal Revenue by Type (2027-2032)
  5. 8.3 North America Gastrointestinal Revenue Share by Type (2021-2032)
  6. 8.4 North America Gastrointestinal Revenue by Application (2021-2032)
  7. 8.4.1 North America Gastrointestinal Revenue by Application (2021-2026)
  8. 8.4.2 North America Gastrointestinal Revenue by Application (2027-2032)
  9. 8.5 North America Gastrointestinal Revenue Share by Application (2021-2032)
  10. 8.6 North America Gastrointestinal Revenue by Country
  11. 8.6.1 North America Gastrointestinal Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gastrointestinal Revenue by Country (2021-2026)
  13. 8.6.3 North America Gastrointestinal Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gastrointestinal Revenue (2021-2032)
  2. 9.2 Europe Gastrointestinal Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gastrointestinal Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gastrointestinal Revenue by Type (2027-2032)
  5. 9.3 Europe Gastrointestinal Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gastrointestinal Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gastrointestinal Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gastrointestinal Revenue by Application (2027-2032)
  9. 9.5 Europe Gastrointestinal Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gastrointestinal Revenue by Country
  11. 9.6.1 Europe Gastrointestinal Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gastrointestinal Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gastrointestinal Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gastrointestinal Revenue (2021-2032)
  2. 10.2 China Gastrointestinal Revenue by Type (2021-2032)
  3. 10.2.1 China Gastrointestinal Revenue by Type (2021-2026)
  4. 10.2.2 China Gastrointestinal Revenue by Type (2027-2032)
  5. 10.3 China Gastrointestinal Revenue Share by Type (2021-2032)
  6. 10.4 China Gastrointestinal Revenue by Application (2021-2032)
  7. 10.4.1 China Gastrointestinal Revenue by Application (2021-2026)
  8. 10.4.2 China Gastrointestinal Revenue by Application (2027-2032)
  9. 10.5 China Gastrointestinal Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gastrointestinal Revenue (2021-2032)
  2. 11.2 Asia Gastrointestinal Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gastrointestinal Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gastrointestinal Revenue by Type (2027-2032)
  5. 11.3 Asia Gastrointestinal Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gastrointestinal Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gastrointestinal Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gastrointestinal Revenue by Application (2027-2032)
  9. 11.5 Asia Gastrointestinal Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gastrointestinal Revenue by Country
  11. 11.6.1 Asia Gastrointestinal Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gastrointestinal Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gastrointestinal Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gastrointestinal Revenue (2021-2032)
  2. 12.2 SAMEA Gastrointestinal Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gastrointestinal Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gastrointestinal Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gastrointestinal Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gastrointestinal Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gastrointestinal Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gastrointestinal Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gastrointestinal Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gastrointestinal Revenue by Country
  11. 12.6.1 SAMEA Gastrointestinal Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gastrointestinal Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gastrointestinal Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst